{
    "nctId": "NCT04937660",
    "briefTitle": "Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC",
    "officialTitle": "Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 350,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. \u226518 years or older with diagnosis of adenocarcinoma of the breast with evidence of metastatic /locally advanced disease not amenable to treatment with curative intent.\n2. Documented HR+ (ER+ and/or PR+) tumor based on local standards\n3. Documented HER2- tumor based on local standards\n4. Will initiate treatment with palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s), as first or second line therapy for metastatic/locally advanced BC at enrollment\n5. Patients who in the opinion of the investigator are willing and able to comply with regular clinic visits\n6. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\n1. Patients participating in any interventional clinical trial\n2. Patients on active treatment for malignancies other than metastatic/locally advanced BC at the time of enrollment\n3. Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}